Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sheridan, C. Doubts raised over 'read-through' Duchenne drug mechanism. Nat Biotechnol 31, 771–772 (2013). https://doi.org/10.1038/nbt0913-771
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0913-771
- Springer Nature America, Inc.
This article is cited by
-
Small molecules as therapeutic agents for inborn errors of metabolism
Journal of Inherited Metabolic Disease (2017)
-
Entwicklung neuer Therapien für seltene Erkrankungen
Monatsschrift Kinderheilkunde (2017)
-
Improving clinical trial design for Duchenne muscular dystrophy
BMC Neurology (2015)
-
Effect of Readthrough Treatment in Fibroblasts of Patients Affected by Lysosomal Diseases Caused by Premature Termination Codons
Neurotherapeutics (2015)
-
EMA reconsiders 'read-through' drug against Duchenne muscular dystrophy following appeal
Nature Biotechnology (2014)